Clinical Trial

Phase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBC

Study acronym: ADJUNCT
Withdrawn Phase 2
View on ClinicalTrials.gov →
Why the trial stopped
The interim analysis of the STAR-221 study showed that the domvanalimab combination did not improve overall survival compared to standard of care. No new relevant safety concerns were identified.
Summary
The ADJUNCT is a single-arm, phase II clinical trial to evaluate the safety and efficacy of the combination of zimberelimab, domvanalimab and sacituzumab govitecan as first-line therapy for patients with PD-L1 positive advanced or metastatic triple-negative breast cancer.
Protocol Amendment History 3 changes
critical Trial status changed: Not Yet Recruiting → Withdrawn 2026-05-02
critical Reason stopped changed: — → The interim analysis of the STAR-221 study showed that the domvanalimab combination did not improve overall survival compared to standard of care. No new relevant safety concerns were identified. 2026-05-02
notable Enrollment reduced: 25 -> 0 participants 2026-05-02
Trial Details
NCT Number NCT07134556
Lead Sponsor MedSIR
Conditions Triple Negative Breast Cancer, PDL-1 Positive
Start Date 2026-04
Primary Completion 2028-05-28 (estimated)
Study Completion 2028-12-28 (estimated)
Updated on ClinicalTrials.gov 2026-05-01